Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success

Drug Maker Refiles PCSK9 Inhibitor Leqvio After December CRL

Executive Summary

The company has said coverage under medical benefit could mean $0 copays for many patients, potentially overcoming a hurdle to uptake in the biologic cholesterol market.

You may also be interested in...



Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing

Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.

Novartis Q2 Preview: Where Is The Next Blockbuster Coming From?

Entresto and Cosentyx continue to grow but investors will be looking to see if there are candidates in the current portfolio or pipeline that could join them in the mega-blockbuster club.

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Novartis’s US strategy for inclisiran; Roche under pressure over prices for Actemra in COVID; Lambda coronavirus variant poses new challenge for vaccines; GSK loses its oncology R&D head; and a look at expected Q3 approvals in the US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel